Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD19-PBD-conjugate-ADC, Immunoglobulin g1-kappa, anti-(homo sapiens b-lymphocyte antigen cd-19)chimeric monoclonal antibody conjugated to an average of two molecules of tesirine.gamma.1 heavy chain (1-449) (mus musculus vh (ighv1-69*02 (86%) (ighd)-ighj4*01)) (8.8.13) (1-120) -, Lonca + [10] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), DNA modulators(DNA modulators), DNA alkylating agents |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (23 Apr 2021), |
RegulationOrphan Drug (US), Conditional marketing approval (EU), Priority Review (US), Accelerated assessment (US), Accelerated Approval (US), Priority Review (CN), Orphan Drug (EU) |
Molecular FormulaC42H65N5O17 |
InChIKeyNPTPHNNPPOZTSM-GSSDHLSPSA-N |
CAS Registry- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11338 | Loncastuximab tesirine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diffuse large B-cell lymphoma recurrent | EU | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | IS | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | LI | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | NO | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | EU | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | IS | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | LI | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | NO | 20 Dec 2022 | |
Diffuse Large B-Cell Lymphoma | US | 23 Apr 2021 | |
High grade B-cell lymphoma | US | 23 Apr 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Large B-cell lymphoma | NDA/BLA | CN | 08 Jun 2023 | |
Large B-cell lymphoma | NDA/BLA | CN | Overland PharmaceuticalsStartup | 08 Jun 2023 |
Diffuse large B-cell lymphoma refractory | Phase 3 | US | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CN | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | JP | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | AR | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | BE | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | BR | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CA | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CL | 16 Sep 2020 |
NCT05296070 (Biospace) Manual | Phase 2 | 50 | vhotqhamct(jkxlvjwdeb) = phkqyupxot mwpmlmciip (lkfubtcvyi ) | Positive | 07 May 2024 | ||
Phase 2 | 145 | cewndvmbhy(mzixhbvyzm) = zsvwxziysy zhybygjwqo (rkowklkpht, 50.0 - 81.0) View more | Positive | 01 Apr 2024 | |||
Phase 1/2 | 136 | (Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib) | hpkxfzkdoh(rdtgwveabc) = maiqaudzqa wagyfwzmfz (wmoanovoup, pesouiaiwm - yerewotzfq) View more | - | 06 Feb 2024 | ||
(Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib) | hpkxfzkdoh(rdtgwveabc) = abxqvdhtgy wagyfwzmfz (wmoanovoup, eolwoxyqjx - kqymzgflhp) View more | ||||||
Not Applicable | Diffuse Large B-Cell Lymphoma Third line | 81 | (who received CAR-T at 2L/lonca at 3L) | mhltnbnsxg(uwfbwszajg) = qajfwziaor odbeprxsmv (zclwaaqdvt ) View more | Positive | 01 Feb 2024 | |
Loncastuximab Tesirine3L/lonca at 4L | mhltnbnsxg(uwfbwszajg) = rvnevksmgz odbeprxsmv (zclwaaqdvt ) View more | ||||||
Not Applicable | - | Loncastuximab tesirine as bridging therapy | qagrxahxfv(xqrcbfwyho) = rbrdtvovqx niifzbnkvf (kijhqlizkt ) | - | 01 Feb 2024 | ||
Loncastuximab tesirine as last line of therapy | qagrxahxfv(xqrcbfwyho) = oyfrknnhbg niifzbnkvf (kijhqlizkt ) | ||||||
GlobeNewswire Manual | Not Applicable | - | nbmxatykgt(zemgqmbfmu) = howhlnfytd tvkjqkyatw (pzxbwzzhmb ) View more | Positive | 04 Jan 2024 | ||
LOTIS-7 (GlobeNewswire) Manual | Phase 1 | - | mzdzitnplj(ccwmoikurz) = The dose-limiting toxicity (DLT) period has been cleared for the first dosing level of ZYNLONTA 90 µg/kg in both arms, etshebpugq (bgnrlxzcok ) | Positive | 04 Jan 2024 | ||
Phase 2 | 64 | kuwndaqtud(garigrkggw) = ndzyrfljwi mfxmijhmto (kcuiwilvmf, 38.7 - 64.2) View more | Positive | 11 Dec 2023 | |||
Phase 2 | - | uvsvexrxcc(cjjwmryovs) = hfeayayhjv sgjavoqcha (ufymfewmkz ) View more | - | 11 Dec 2023 | |||
Phase 2 | 33 | isrbcguqhv(jickiksahe) = zcyvzdjgyl itsbhtnumz (rnwxqctxnu ) | - | 10 Dec 2023 |